Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.
Clarity Pharmaceuticals reported that another participant in the Phase II Cohort Expansion of its SECuRE trial for metastatic castration-resistant prostate cancer achieved undetectable prostate-specific antigen after the first cycle and a negative PSMA PET scan after the second cycle of 67Cu-SAR-bisPSMA. The 76-year-old patient, who had long-standing, progressive disease despite prior surgery, radiotherapy and systemic treatment, experienced only mild, mostly resolving adverse events with no hematological or renal toxicity observed.
This case marks the fifth participant in Clarity’s SAR-bisPSMA theranostic program to reach undetectable disease by radiographic assessment, reinforcing the emerging efficacy signal and safety profile of 67Cu-SAR-bisPSMA. Clarity also reported sustained undetectable disease in a previously announced Phase II participant after a fourth treatment cycle, and said enrollment in the SECuRE Cohort Expansion will continue through 2026 as it advances planning for a Phase III registrational trial, underscoring growing clinical momentum in its prostate cancer franchise.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is an ASX-listed clinical-stage radiopharmaceutical company focused on developing next-generation theranostic products for cancer. Its lead programs target metastatic castration-resistant prostate cancer using copper-based PSMA-directed agents designed to both image and treat disease, aiming to improve outcomes versus existing prostate cancer therapies.
Average Trading Volume: 2,381,372
Technical Sentiment Signal: Hold
Current Market Cap: A$1.26B
For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.